Literature DB >> 7531854

Plasma protein binding of risperidone and its distribution in blood.

G Mannens1, W Meuldermans, E Snoeck, J Heykants.   

Abstract

The plasma protein binding of the new antipsychotic risperidone and of its active metabolite 9-hydroxy-risperidone was studied in vitro by equilibrium dialysis. Risperidone was 90.0% bound in human plasma, 88.2% in rat plasma and 91.7% in dog plasma. The protein binding of 9-hydroxy-risperidone was lower and averaged 77.4% in human plasma, 74.7% in rat plasma and 79.7% in dog plasma. In human plasma, the protein binding of risperidone was independent of the drug concentration up to 200 ng/ml. The binding of risperidone increased at higher pH values. Risperidone was bound to both albumin and alpha 1-acid glycoprotein. The plasma protein binding of risperidone and 9-hydroxy-risperidone in the elderly was not significantly different from that in young subjects. Plasma protein binding differences between patients with hepatic or renal impairment and healthy subjects were either not significant or rather small. The blood to plasma concentration ratio of risperidone averaged 0.67 in man, 0.51 in dogs and 0.78 in rats. Displacement interactions of risperidone and 9-hydroxy-risperidone with other drugs were minimal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531854     DOI: 10.1007/bf02244986

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

Review 1.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

4.  Biochemical profile of risperidone, a new antipsychotic.

Authors:  J E Leysen; W Gommeren; A Eens; D de Chaffoy de Courcelles; J C Stoof; P A Janssen
Journal:  J Pharmacol Exp Ther       Date:  1988-11       Impact factor: 4.030

Review 5.  Protein binding displacement interactions and their clinical importance.

Authors:  J C McElnay; P F D'Arcy
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

6.  Pilot clinical investigation of risperidone in the treatment of psychotic patients.

Authors:  Y G Gelders; S L Heylen; G Vanden Bussche; A J Reyntjens; P A Janssen
Journal:  Pharmacopsychiatry       Date:  1990-09       Impact factor: 5.788

7.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.

Authors:  A Claus; J Bollen; H De Cuyper; M Eneman; M Malfroid; J Peuskens; S Heylen
Journal:  Acta Psychiatr Scand       Date:  1992-04       Impact factor: 6.392

8.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Authors:  P A Janssen; C J Niemegeers; F Awouters; K H Schellekens; A A Megens; T F Meert
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

9.  The metabolism and excretion of risperidone after oral administration in rats and dogs.

Authors:  W Meuldermans; J Hendrickx; G Mannens; K Lavrijsen; C Janssen; J Bracke; L Le Jeune; W Lauwers; J Heykants
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

10.  Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

Authors:  L E van Beijsterveldt; R J Geerts; J E Leysen; A A Megens; H M Van den Eynde; W E Meuldermans; J J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

View more
  23 in total

Review 1.  Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.

Authors:  N Bhana; C M Spencer
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Developing in vitro-in vivo correlation of risperidone immediate release tablet.

Authors:  Yardi Saibi; Hitoshi Sato; Hidehisa Tachiki
Journal:  AAPS PharmSciTech       Date:  2012-06-14       Impact factor: 3.246

Review 3.  Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

4.  Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders.

Authors:  An Thyssen; An Vermeulen; Eliane Fuseau; Marc-Antoine Fabre; Erik Mannaert
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

5.  Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.

Authors:  Magdalena Kozielska; Martin Johnson; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2012-03-22       Impact factor: 4.200

6.  A Novel Eutectic-Based Transdermal Delivery System for Risperidone.

Authors:  Faisal Al-Akayleh; Samer Adwan; Mai Khanfar; Nasir Idkaidek; Mayyas Al-Remawi
Journal:  AAPS PharmSciTech       Date:  2020-11-22       Impact factor: 3.246

7.  Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Hugh A Barton; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

8.  Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.

Authors:  Celine M Laffont; Roberto Gomeni; Bo Zheng; Christian Heidbreder; Paul J Fudala; Azmi F Nasser
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

Review 9.  Paliperidone: a review of clinical trial data and clinical implications.

Authors:  Sheng-Min Wang; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Chi-Un Pae; W Wolfgang Fleischhacker
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

Review 10.  Long-acting risperidone: a review of its use in schizophrenia.

Authors:  Tracy Swainston Harrison; Karen L Goa
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.